This corresponds with studies indicating that TNF-α inhibitors are especially useful in managing inflammation in seronegative RA patients, reinforcing the notion that TNF-α plays a more pivotal role in disease activity for these individuals than autoantibody-mediated mechanisms in seropositive RA. Here, TNF is linked to rheumatoid arthritis.